Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)

Growth (Per Share)

Revenue 5Y—
Revenue 3Y—
Earnings 5Y—
Earnings 3Y—
Dividend 5Y—
Dividend 3Y—

Capital Efficiency

ROIC—
ROE—
ROA—
ROTA—

Capital Structure

Market Cap4.92B
EV4.92B
Cash—
Current Ratio—
Debt/Equity—
Net Debt/EBITDA—
Show More

Select a metric from the list below to chart it

Income Statement
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
TTM
Revenue
277.6
390.5
434.6
443.1
798.4
736.1
445.0
458.1
452.7
439.1
Revenue % Chg.
45.7%
40.7%
11.3%
1.9%
80.2%
-7.8%
-39.6%
3.0%
-1.2%
-2.5%
Cost of Revenue
102.8
143.7
179.7
130.4
203.2
196.2
115.5
120.8
104.8
98.7
Gross Profit
174.8
246.8
254.9
312.7
595.2
539.9
329.5
337.3
347.9
340.4
Gross Profit Margin
63.0%
63.2%
58.7%
70.6%
74.5%
73.4%
74.0%
73.6%
76.9%
77.5%
R&D Expenses
8.1
13.1
14.4
11.8
17.9
27.1
18.3
14.2
14.7
13.9
Selling, General, & Admin Expenses
80.7
87.5
83.3
201.3
468.0
434.2
305.3
294.9
307.7
300.7
Other Expenses
12.0
20.9
21.6
18.6
16.8
13.9
8.4
2.6
5.8
5.2
Operating Income
74.0
125.3
135.5
81.0
92.4
46.6
114.3
22.8
-16.2
-35.2
Operating Income Margin
26.6%
32.1%
31.2%
18.3%
11.6%
6.3%
25.7%
5.0%
-3.6%
-8.0%
Total Other Income/Expenses Net
5.8
-5.1
-10.5
-26.9
-66.4
-425.9
-32.0
-10.3
-23.0
-1.6
Income Before Tax
79.8
120.3
125.0
54.1
26.1
-379.3
82.3
12.5
-39.3
-36.8
Income Before Tax Margin
28.7%
30.8%
28.8%
12.2%
3.3%
-51.5%
18.5%
2.7%
-8.7%
-8.4%
Income Tax Expense
13.4
18.2
18.9
9.6
7.3
7.4
22.8
4.7
2.9
2.7
Net Income
64.6
96.8
104.4
45.1
18.3
-386.7
58.3
6.6
-42.2
-40.1
Net Income Margin
23.3%
24.8%
24.0%
10.2%
2.3%
-52.5%
13.1%
1.4%
-9.3%
-9.1%
Weighted Avg. Shares Out
2,113.2
715.0
2,178.9
2,197.8
2,197.1
2,198.2
2,198.1
2,197.2
2,198.7
—
EPS
0.0
0.1
0.0
0.0
0.0
-0.2
0.0
0.0
-0.0
—
EPS % Chg.
94.4%
342.8%
-64.6%
-57.2%
-59.3%
—
—
-88.6%
—
—
Weighted Avg. Shares Out Dil
2,113.2
732.1
2,198.3
2,197.8
2,197.1
2,198.2
2,198.1
2,197.2
2,198.7
—
EPS Diluted
0.0
0.1
0.0
0.0
0.0
-0.2
0.0
0.0
-0.0
—
Interest Income
0.5
0.6
1.1
1.3
2.1
2.6
2.4
2.5
3.0
2.9
Interest Expense
4.0
12.8
15.9
24.3
22.8
21.3
12.9
10.4
10.0
9.8
EBIT
76.2
108.2
110.3
31.1
5.4
-398.0
71.8
4.6
-46.3
-43.6
EBIT Margin
27.5%
27.7%
25.4%
7.0%
0.7%
-54.1%
16.1%
1.0%
-10.2%
-9.9%
Depreciation & Amortization
13.5
20.9
22.5
25.6
26.8
26.4
21.7
21.0
18.9
18.5
EBITDA
89.7
129.1
132.8
56.7
32.2
-371.6
93.6
25.7
-27.3
-25.1
EBITDA Margin
32.3%
33.1%
30.6%
12.8%
4.0%
-50.5%
21.0%
5.6%
-6.0%
-5.7%